Doc code: IDS

Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/05a (07-09)
Approved for use through 07/31/2012 OMB 0651-0031
formation Disclosure Statement (IDS) Filed
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10560069
\$\$\$P~~~\$\$\$\$~~\$\\\\\\\\\\\\\\\\\\\\\\\\\	Filing Date		2005-12-09
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Steph	en John KENT
(Not for submission under 37 CFR 1.99)	Art Unit		1644
,	Examiner Name	Amy E	Juedes
	Attorney Docket Numb	er	00704.8010.US00

NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T 5		
	1	PIOT, P., et al., The Global Impact of HIV/AIDS, Nature, (2001), 410(6831); pp 968-73.			
	2	UNAIDS, Global Estimates of HIV/AIDS Epidemic as of end (2002), 2003, UNAIDS.			
	3	BORROW, P., et al., Virus-Specific CD8+ Cytotoxic T-Lymphocyte Activity Associated, J Virol, (1994), 68(9): pp 6103-10.			
	4	KOUP, R. A., et al., Temporal Association of Cellular Immune Responses with the Initial Control of Viremia, J Virol, (1994) 68(7): pp 4650-5.			
	5	MUSEY, L., et al., Cytotoxic-T-Cell Responses, Viral Load, and Disease Progression in Early Human, N. Engl J Med, (1997), 337(18): pp 1267-74.			
	6	OGG, G. S., et al., Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load, Science, (1998), 279 (5359); pp 2103-6.			
	7	CARMICHAEL, A., et al., Quantitative Analysis of the Human Innunodeficiency Virus Type 1, J Exp Med, (1993), 177(2); pp 249-56.			
	8	RINALDO, C., et al., High Levels of Anti-Human Immunodeficiency Virus Type 1 (HIV-1), J Virol, (1995); 69(9): pp 5838-42.			

(Not for submission under 37 CFR 1.99)

Application Number		10560069
Filing Date		2005-12-09
First Named Inventor	Steph	en John KENT
Art Unit		1644
Examiner Name Amy I		E. Juedes
Attorney Docket Numb	er	00704,8010,US00

	9		HAY, C. M., et al., Lack of Viral Escape and Defective In Vivo Activation of Human Immunodeficiency, J Virol, (1999), 73(7): pp 5509-19.	
	10)	JOHNSON, P. R., et al., Inactivated Whole SIV Vaccine in Macaques: Evaluation of Protective Efficacy, AIDS Research and Human Retroviruses (1992) 8(8): pp 1501-5.	
	11		CRANAGE, M. P., et al., Studies on the Specificity of the Vaccine Effect Elicited by Inactivated Simian, AIDS Research and Human Retroviruses, (1993), 9(1): pp 13-22.	
	12	2	LUKE, W., et al., Simian Immunodeficiency Virus (SIV) gp130 Oligomers Protect Rhesus Macaques, (1996), 216(2); pp 444-50.	
	13	3	MOOIJ, P., et al., A Clinically Relevant HIV-1 subunit Vaccine Protects Rhesus Macaques From In Vivo,,(1998), 12 (5): pp F15-22:	
	14	4	VaxGen, L, VaxGen Announces Initial Results of its Phase III AIDS Vaccine Trial. (2003) PR Newswire.	
	15	õ	KENT, S. J., Vaccination with Attenuated Simian Immunodeficiency Virus by DNA Inoculation, J Virol. (2001), 75(23): pp 11930-4.	
	16	3	KENT, S. J., et al., Enhanced T-Cell Immunogenicity of Protective Efficacy of a Human Immunodeficiency Virus, J Virol, (1998), 72(12): pp 10180-8.	
	17	7	SANTRA, S., et al., Prior Vaccination Increases the Epitopic Breadth of the Cytotoxic T-Lymphocyte Response, J Virol, (2002), 76(12): pp 6376-81.	
	18	3	ESTCOURT, M. J., et al, Prime-boost Immunization Generates a High Frequency, High-avidity CD8+,, Int Immunol, (2002), 14(1): pp 31-7.	
	19)	MARZO, A. L., et al., Tumor-Specific CD4+ T Cells Have a Major "Post-Licensing" Role in CTL Mediated,J Immunol, (2000), 165(11): pp 6047-55.	
. '		m	······································	

(Not for submission under 37 CFR 1.99)

Application Number	10560069
Filing Date	2005-12-09
First Named Inventor	Stephen John KENT
Art Unit	1644
Examiner Name	Amy E. Juedes
Attorney Docket Numb	er 00704,8010.US00

		NELSON, D. J., et al., Tumor Progression Despite Efficient Tumor Antigen Cross-Presentation and Effective, J Immunol, (2001), 166(9): pp 5557-66.	
2	21	RITCHIE, D. S., et al., Dendritic Cell Elimination as an Assay of Cytotoxic T Lymphocyte, J Immunol Methods, (2000), 246(1-2): pp 109-17.	
	22	CARBONE, F. R., et al., Induction of Ovalbumin-Specific Cytotoxic T Cells By In Vivo Peptide, J Exp Med, (1989), 169(3): pp 603-12.	
,	23	CARBONE, F. R., et al., Induction of Cytotoxic T lymphocytes By Primary In Vivo Stimulation with Peptides, J Exp. Med, (1988), 167(6): pp 1767-79.	()
á	24	KAST, W. M., et al, Protection Against Lethal Sendai Virus Infection by In Vivo Priming of Virus-Specific, Proc Natl Acad Sci USA, (1991), 88(6): pp 2283-7	
	25	SCHULZ, M., et al, Peptide-Induced Antiviral Protection by Cytotoxic T Cells, Proc Natl Acad Sci USA, (1991), 88(3): pp 991-3.	
2	26	FELTKAMP, M. C., e tal., Vaccination with Cytotoxic T Lymphocyte Epitope-Containing Peptide Protects, Eur J Immunol, (1993), 23(9): pp 2242-9.	
	27	CELLUZZI, C. M., et al., Peptide-Pulsed Dendritic Cells Induce Antigen-Specific, CTL-Mediated Protective, J Exp Med, (1996), 183(1): pp 283-7.	
	28	KEARNEY, E. R., et al, Visualization of Peptide-Specific T Cell Immunity and Peripheral Tolerance, Immunity, (1994), 1(4): pp 327-39.	
	29	AICHELE, P., et al., T Cell Priming Versus T Cell Tolerance Induced By Synthetic Peptides, J Exp Med, (1995), 182 (1): pp 261-6.	
	30	TOES, R. E., et al., Peptide Vaccination Can Lead to Enhanced Tumor Growth Through Specific T-Cell, J. Immunol, (1996), 156(10): pp 3911-8.	

(Not for submission under 37 CFR 1.99)

nber		10560069		
	*****	2005-12-09		
ventor	Steph	hen John KENT		
	h	1644		
Examiner Name Attorney Docket Numbe		E. Juedes		
		00704,8010.US00		
	е	ventor Steph		

31	TOES, R. E., et al., Enhanced Tumor Outgrowth after Peptide Vaccination, Proc Natl Acad Sci USA, (1996), 93(15): pp 7855-60.	
32	DALE, C. J., et al., Chimeric Human Papilloma Virus-Simian/Human Immunodeficiency Virus Virus-Like-Paritcle Virology, (2002), 301(1): pp 176-87.	
33	JIN, X., et al., Dramatic Rise in Plasma Viremia After CD8+ T Cell Depletion in Simian, J Exp Med, (1999), 189(6): pp 991-8:	
34	CARBONE, F. R., et al., Class I-Restricted Processing and Presentation of Exogenous Cell-Associated, J Exp Med, (1990), 171(2): 99 377-87.	
35	LARSSON, M., et al., Efficiency of Cross Presentation of Vaccinia Virus-Derived Antigens by Human, Eur J Immunol, (2001), 31(12): pp 3432-42.	
36	CHEN, Q., et al., A Direct Comparison of Cytolytic T-Lymphocyte Responses to Melan-A Peptides in Vitro Melanoma Res, (2000), 10(1): pp 16-25.	
37	LU, W., et al., Therapeutic Dendritic-Cell Vaccine for Simian AIDS, Nat Med, (2003), 9(1): pp 27-32.	٦
38	POSPISILOV, D., et al., Generation of Functional Dendritic Cells For Potential Use in the Treatment, Cancer Immunol Immunother, (2002), 51(2): pp 72-8.	
39	MELIEF, C. J., et al., Effective Therapeutic Anticancer Vaccines Based on Precision Guiding of Cytolytic, Immunol Rev, (2002), 188(1): pp 177-82.	
40	MEHLHOP, E., et al., Enhanced In Vitro Stimulation of Rhesus Macaque Dendritic Cell for ActivationJ Immunol Methods, (2002), 260(1-2): pp 219-34.	
41	SAPP, M., et al., Dendritic Cells Generated from Blood Monocytes of HIV-1 Patients are Not Infected and act, Immunol Lett, (1999), 66(1-3): pp 121-8.	

(Not for submission under 37 CFR 1.99)

Application Number	10560069
Filing Date	2005-12-09
First Named Inventor	Stephen John KENT
Art Unit	1644
Examiner Name	Amy E. Juedes
Attorney Docket Number	or 00704.8010.US00

42	CHOUGNET, C., et al., Normal Immune Function of Monocyte-Derived Dendritic Cells from HIV-Infected Individuals, J Immunol, (1999), 163(3): pp 1666-73.	
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		